|
|
News Breaks | | | | March 6, 2013 | | 09:25 EDT |  | OGXI, OGXI | OncoGenex to host conference call
Conference call to discuss 4Q12 earnings and provide an update on clinical development program will be held on March 7 at 4:30 pm. Webcast Link | |
|
News For OGXI From The Last 14 Days Check below for free stories on OGXI the last two weeks. |
|
|
| May 23, 2013 | | 07:12 EDT |  | OGXI | OncoGenex plans initiation of Ceder clinical trial for OGX-427
OncoGenex Pharmaceuticals announced plans for the initiation of the Cedar clinical trial, an investigator-sponsored, randomized, open-label Phase 2 trial evaluating OGX-427 in previously untreated patients with advanced squamous cell lung cancer. This trial will be the seventh randomized Phase 2 clinical trial evaluating OGX-427 in the treatment of advanced cancers and will investigate whether adding OGX-427 to gemcitabine and carboplatin therapy can extend progression-free survival, or PFS, outcomes. Cedar will randomize approximately 140 patients to receive either OGX-427 plus gemcitabine and carboplatin therapy, or gemcitabine and carboplatin therapy alone. The primary objective will be PFS, with secondary objectives to evaluate tumor response rates, overall survival, safety, tolerability, and health-related quality of life. Additional analyses will be conducted to determine the effect of therapy on heat shock protein 27 levels and to explore potential biomarkers that may help predict response to treatment. | | | May 22, 2013 | | 07:35 EDT | | OGXI | Bloom Burton & Co. to host a conference
 Subscribe for More Information | |
|
|
|
|
|
|
